Study testing dinutuximab beta with chemotherapy for neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 months old and under 18 years old.
- Your weight must be more than 12 kg (about 26 pounds).
- Your cancer must be a type called neuroblastoma that has spread to other parts of the body (Stage M).
- You must not have had any prior cancer treatment for neuroblastoma.
- Your liver and kidney function must be within safe limits based on blood tests.
- Your heart function must be normal as shown on an ultrasound or similar test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This study is a long-term safety and follow-up registry. It tracks how dinutuximab beta is doing in real-world patients with high-risk neuroblastoma over time.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.